<div id="readability-page-1"><p>→ Warning: Don’t type “Trump” on your phone (Feds could be watching) <span><span><span>(From Paradigm Press)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDgx"/></span></p><div id="articlecontent"> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/dianthus-therapeutics-inc-logo-1200x675.png/query-dj0yMDIzMTAwMjEzMjEwNA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1200" height="675" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/dianthus-therapeutics-inc-logo-1200x675.png/query-dj0yMDIzMTAwMjEzMjEwNA"/>Dianthus Therapeutics, Inc. (NASDAQ:DNTH - Get Free Report) shares fell 4.6% on Wednesday . The stock traded as low as $23.02 and last traded at $23.02. 52,063 shares were traded during mid-day trading, a decline of 63% from the average session volume of 141,196 shares. The stock had previously closed at $24.14.</p><div><p><span></span><span>Get <strong>Dianthus Therapeutics</strong> alerts:</span></p></div><h2>Analyst Ratings Changes</h2><p>Several research firms have weighed in on DNTH. Jefferies Financial Group increased their target price on shares of Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, March 22nd. Wedbush increased their target price on shares of Dianthus Therapeutics from $24.00 to $33.00 and gave the stock an &#34;outperform&#34; rating in a report on Friday, March 22nd. Finally, Stifel Nicolaus began coverage on shares of Dianthus Therapeutics in a report on Thursday, February 15th. They set a &#34;buy&#34; rating and a $44.00 price objective on the stock. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of &#34;Buy&#34; and a consensus target price of $37.00.</p><p><b>View Our Latest Research Report on DNTH</b></p><h2>Dianthus Therapeutics Trading Down 5.1 %</h2><p>The business's fifty day moving average is $25.84 and its 200 day moving average is $17.07. </p><p>Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last issued its quarterly earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.11) by $0.40. The business had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.73 million. Analysts predict that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current year. </p><h2>Institutional Investors Weigh In On Dianthus Therapeutics</h2><div><div><p><span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDgx"/></span></p><div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/med_generic_stock_0729758580.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="720" height="540" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/images/webpush/files/med_generic_stock_0729758580.jpg"/></p></div><div><p><b>Ad </b> Paradigm Press</p><p>Warning: Don’t type “Trump” on your phone (Feds could be watching)</p><p>This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...</p><p>Watch my unredacted video about what I think is coming next right here</p></div></div></div><p>Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. FMR LLC bought a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth about $28,961,000. Avidity Partners Management LP acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $16,644,000. Atlas Venture Life Science Advisors LLC acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at approximately $3,240,000. Vestal Point Capital LP acquired a new position in Dianthus Therapeutics during the 4th quarter worth approximately $1,404,000. Finally, Vanguard Group Inc. acquired a new position in Dianthus Therapeutics during the 3rd quarter worth approximately $1,734,000. 47.53% of the stock is currently owned by institutional investors and hedge funds. </p><h2>About Dianthus Therapeutics</h2><p> (Get Free Report)</p><p>Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Dianthus Therapeutics</li><li>What is Put Option Volume?</li><li>J.B. Hunt Hits the Skids: Lower Prices to Come</li><li>Bank Stocks - Best Bank Stocks to Invest In</li><li>Predicting a Bear Market: 7 Signs and Why it's Tough to Do</li><li>How to Calculate Stock Profit </li><li>Abbott Laboratories Outlook is Healthy: Buy the Dip</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Warning: Don’t type “Trump” on your phone (Feds could be watching) <span><span><span>(From Paradigm Press)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDgx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD03NDgx"/></span></p><h2>Should you invest $1,000 in Dianthus Therapeutics right now?</h2><p>Before you consider Dianthus Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.</p><p>While Dianthus Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here </p><div><div><div><p><img height="209" width="170" src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/premium-reports/small_20231017095516_reportpreview2023-10-ten-best-stocks-2024-cover.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/premium-reports/small_20231017095516_reportpreview2023-10-ten-best-stocks-2024-cover.png"/></p></div><div><div><p>10 Best Stocks to Own in 2024</p><p>Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. </p><p>Get This Free Report</p></div></div></div></div> </div></div>

DNTH

NDAQ

<p>Dianthus Therapeutics (NASDAQ:DNTH) saw a 4.6% decrease in its stock price. The company has received positive ratings and target price increases from several research firms. Institutional investors have also shown interest in the company. Dianthus Therapeutics is a clinical-stage biotechnology company developing complement therapeutics for autoimmune and inflammatory diseases.</p>

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 4.6%